Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Completed 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Classical hematology 4

Conditions

Hemophilia A 4

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × emicizumab × Clear all
NCT03020160 2023-01-11

HAVEN 4

Hoffmann-La Roche

Phase 3 Completed
48 enrolled 44 charts 1 FDA
Classical hematology

Hemophilia A

NCT02847637 2022-11-16

HAVEN 3

Hoffmann-La Roche

Phase 3 Completed
152 enrolled 46 charts 1 FDA
Classical hematology

Hemophilia A

NCT02622321 2021-06-24

HAVEN 1

Hoffmann-La Roche

Phase 3 Completed
113 enrolled 45 charts 1 FDA
Classical hematology

Hemophilia A

NCT02795767 2021-06-02

HAVEN 2

Hoffmann-La Roche

Phase 3 Completed
88 enrolled 65 charts 1 FDA
Classical hematology

Hemophilia A

Data powered by HemOnc (CC BY 4.0) Colophon âš¡